By Martin Baccardax
Novartis AG said Monday that it has received approval from the European Commission for a blood cancer treatment known as Rixathon, a biosimilar version of Roche AG’s blockbuster Rituxan that generated around US$7.5 billion in sales last year.
Sandoz, the biosimilar division of Swiss drugmaker Novartis, said the approval allows for the use of Rixathon in Europe and represents a “big win” for patients with “blood cancers or immunological…
June 19, 2017 at 01:30PM http://ift.tt/2shieTd
#3Novices #News #OnlineMedia #China #LifeStyle 3Novices China